<DOC>
	<DOCNO>NCT01462942</DOCNO>
	<brief_summary>The objective provide data support use LAS40464 efficacious safe maintenance bronchodilator treatment patient Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Long-term Efficacy Safety Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination</brief_title>
	<detailed_description>This Phase III study seek confirm long-term bronchodilator efficacy effect COPD relate health status secondary parameter well safety two dos combination aclidinium bromide/formoterol FDC ( FDC 400/12 μg 400/6 μg ) compare aclidinium bromide monotherapy 400 μg , formoterol monotherapy 12 μg placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating female age ≥40 . Women childbearing potential allow enter trial show negative serum pregnancy test Screening Visit use , last two month Screening Visit , least one medically approve highly effective method birth control define result low failure rate ( i.e le 1 % per year ) use consistently correctly implant , injectables , oral contraceptive combine least one barrier method , hormonal Intrauterine Devices ( IUDs ) , sexual abstinence vasectomy partner . Current excigarette smoker , smoke history least 10 packyears . Patient clinical diagnosis stable COPD accord Global Initiative Chronic Lung Disease `` GOLD '' Guidelines Screening Visit . Patient whose FEV1/FVC ( Forced Vital Capacity ) Screening Visit measure 1015 minute post inhalation 400 microgram salbutamol &lt; 70 % ( i.e. , 100 x Postsalbutamol FEV1 /FVC &lt; 70 % ) . Patient diagnosis moderate severe COPD accord GOLD Guidelines classification ( stage II III ) Screening Visit : FEV1 measure 1015 minute post inhalation 400 micro gram salbutamol 30 % &lt; FEV1 &lt; 80 % predict normal value ( i.e. , 100 x Postsalbutamol FEV1/ Predicted FEV1 must &lt; 80 % ≥ 30 % ) . Patient must able perform repeatable pulmonary function test FEV1 accord American Thoracic Society/European Respiratory Society `` ATS/ERS '' 2005 criterion Screening Visit . Patient eligible able participate trial consent write purpose nature investigation explain . History current diagnosis asthma . Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation 6 week Screening Visit . Patient hospitalise COPD exacerbation within 3 month prior Screening Visit . Clinically significant respiratory condition define : Known active tuberculosis . History interstitial lung massive pulmonary thromboembolic disease . Pulmonary resection lung volume reduction surgery within 12 month prior Screening Visit . History lung transplantation . History bronchiectasis secondary respiratory diseases others COPD ( e.g. , cystic fibrosis , Kartagener 's syndrome , etc ) . Known a1antitrypsin deficiency . Patients Investigator 's opinion might need start pulmonary rehabilitation program study and/or patient started/finished within 3 month prior screen . Use longterm oxygen therapy ( ≥ 15 hours/day ) . Patients maintain regular day/night , waking/sleeping cycle include night shift worker ( eg , history sleep apnoea syndrome , condition relate sleep disturbance restlesslegs syndrome somnambulism ) . Clinically significant cardiovascular condition define : Myocardial infarction within 6 month prior screen . Thoracic surgery within 12 month prior screen . Unstable angina unstable arrhythmia require change pharmacological therapy intervention within 12 month prior screen , newly diagnose arrhythmia within previous 3 month prior screen . Hospitalisation within 12 month prior screen heart failure functional class III ( marked limitation activity comfortable rest ) IV ( need complete rest , confinement bed chair , discomfort physical activity presence symptom rest ) per New York Heart Association . Patients ( without pharmacological therapy ) rest systolic blood pressure ( SBP ) ≥200 mmHg , rest diastolic blood pressure ( DBP ) ≥120 mmHg , rest heart rate ≥105 beat per minute ( bpm ) screen Visit 1 prior randomisation . Patients interval corrected heart rate `` QTc '' [ calculate accord formula ( QTc=QT/RR1/2 ) &gt; 470 msec indicate centralised reading report assess Screening Visit . Patients clinically relevant abnormality clinical laboratory test , ECG parameter ( QT interval correct use Bazett 's formula [ QTcB ] ) physical examination screening , abnormality define disease state list exclusion criterion , except related COPD . Patients history hypersensitivity reaction inhale anticholinergic , sympathomimetic amine , inhaled medication component thereof ( include report paradoxical bronchospasm ) . Patients know narrowangle glaucoma , symptomatic bladder neck obstruction acute urinary retention . Patients symptomatic nonstable prostate hypertrophy . ( However , patient wellcontrolled , stable , asymptomatic benign prostatic hypertrophy exclude ) . Patients know uncontrolled history infection human immunodeficiency virus and/or active hepatitis . Current diagnosis cancer basal squamous cell skin cancer . Life expectancy less 1 year . Patients serious uncontrolled physical mental dysfunction , judge Investigator , could place patient high risk his/her participation study , could confound result study , likely prevent patient comply requirement study , complete study . Patients history ( within 2 year prior screen ) drug and/or alcohol abuse might prevent study compliance base Investigator judgment . Patients unlikely cooperative ( eg , take medication , complete Patient Diaries attend clinic require time ) . Patients unable properly use DPI pMDI inhaler device perform spirometry measurement . Patients previously randomise study involve aclidinium bromide/formoterol FDC . Patients previously randomise study involve aclidinium bromide monotherapy except participation finish least 6 month screen . Patients treat investigational drug within 30 day ( 6 halflives , whichever long ) prior screen . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication . Patients unable give consent , patient consent age guardianship , vulnerable patient . Patients employ , relatives employee study centre , Almirall Forest Laboratories . Any condition , Investigator 's opinion , might indicate patient unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Bronchitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>Emphysema</keyword>
</DOC>